References of "Vanderkerken, Karin"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors.
Otjacques, Eléonore ULg; Binsfeld, Marilène ULg; Rocks, Natacha ULg et al

in PLoS ONE (2013), 8(5), 62818

Mithramycin (MTM), a cytotoxic compound, is currently being investigated for its anti-angiogenic activity that seems to be mediated through an inhibition of the transcription factor SP1. In this study we ... [more ▼]

Mithramycin (MTM), a cytotoxic compound, is currently being investigated for its anti-angiogenic activity that seems to be mediated through an inhibition of the transcription factor SP1. In this study we evaluated its anti-myeloma effects in the syngenic 5TGM1 model in vitro as well as in vivo. In vitro, MTM inhibited DNA synthesis of 5TGM1 cells with an IC50 of 400 nM and induced an arrest in cell cycle progression at the G1/S transition point. Western-blot revealed an up-regulation of p53, p21 and p27 and an inhibition of c-Myc, while SP1 remained unaffected. In rat aortic ring assays, a strong anti-angiogenic effect was seen, which could be explained by a decrease of VEGF production and an up-regulation of anti-angiogenic proteins such as IP10 after MTM treatment. The administration of MTM to mice injected with 5TGM1 decreased 5TGM1 cell invasion into bone marrow and myeloma neovascularisation. These data suggest that MTM displays anti-myeloma and anti-angiogenic effects that are not mediated by an inhibition of SP1 but rather through c-Myc inhibition and p53 activation. [less ▲]

Detailed reference viewed: 32 (5 ULg)
Full Text
Peer Reviewed
See detailThe effects of forodesine in murine and human multiple myeloma cells
Bieghs, Liesbeth; Caers, Jo ULg; De Bruyne, Elke et al

in Advances in Hematology (2010)

Detailed reference viewed: 22 (4 ULg)
Full Text
Peer Reviewed
See detailThymosin Beta 4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma
Caers, Jo ULg; Hose, Dirk; Kuijpers, Ine et al

in Haematologica (2010), 95(1), 163-167

Detailed reference viewed: 18 (1 ULg)
Full Text
Peer Reviewed
See detailThymosin beta4 in multiple myeloma: friend or foe
Caers, Jo ULg; Otjacques, Eléonore ULg; Hose, Dirk et al

in Annals of the New York Academy of Sciences (2010), 1194(1), 125-130

Detailed reference viewed: 22 (6 ULg)
Peer Reviewed
See detailDecreased Thymosin Beta 4 Expression Results in Poor Prognosis and Decreased Survival in Multiple Myeloma
CAERS, Jo ULg; Hose, Dirk; Kuipers, Ine et al

Poster (2008)

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailUnraveling the biology of MM disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment.
Caers, Jo ULg; Van Valckenborgh, Els; Menu, Eline et al

in Bulletin du Cancer (2008), 95(3), 301-13

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailAntitumor and anti-angiogenic effects of aplidin in the 5T33MM model, syngeneic model of multiple myeloma
Caers, Jo ULg; De Raeve, Hendrik; Lepage, Doreen et al

in British Journal of Cancer (2008), 98(12), 1966-74

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailMultiple Myeloma, an update on diagnosis and treatment.
Caers, Jo ULg; Vande Broek, Isabelle; De Raeve, Hendrik et al

in European Journal of Haematology (2008), 81(5), 329-343

Detailed reference viewed: 8 (3 ULg)
Full Text
Peer Reviewed
See detailNeighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells
CAERS, Jo ULg; Deleu, Sara; Belaid, Zakia et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2007), 21(7), 1580-4

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailDe bijdrage van muismodellen bij studies naar multipel myeloom
Vanderkerken, Karin; Van Valckenborgh, Els; Menu, Eline et al

in Nederlands Tijdschrift voor Hematologie (2007), 4(4), 193-143

Detailed reference viewed: 20 (0 ULg)
Full Text
Peer Reviewed
See detailEndothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.
De Bruyne, Elke; Andersen, T. L.; De Raeve, Hendrik et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2006), 20(10), 1870-9

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailThe involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model
Caers, Jo ULg; Günthert, Ursula; De Raeve, Hendrik et al

in British Journal of Haematology (2006), 132((4)), 469-77

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailAc-SDKP: linking cardiac remodelling to haematological malignancies.
Caers, Jo ULg; Vanderkerken, Karin

in Leukemia & Lymphoma (2006), 47(9), 1732-3

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailOf mice and men: disease models of multiple myeloma
Caers, Jo ULg; Asosingh, Kewal; Van Camp, Ben et al

in Drugs Discovery Today: disease models (2005), 1(4), 373-380

Detailed reference viewed: 18 (1 ULg)
Peer Reviewed
See detailExpression of osteopontin and its receptor the alphavbeta3 integrin in the 5TMM myeloma model
CAERS, Jo ULg; De Raeve, Hendrik; Asosingh, Kewal et al

Poster (2004, September 17)

NA

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailMultifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model
Van Valckenborgh, Els; Croucher, Peter I.; De Raeve, Hendrik et al

in American Journal of Pathology (2004), 165(3), 869-878

Matrix metalloproteinases (MMPs) are known to play a role in cell growth, invasion, angiogenesis, metastasis, and bone degradation, all important events in the pathogenesis of cancer. Multiple myeloma is ... [more ▼]

Matrix metalloproteinases (MMPs) are known to play a role in cell growth, invasion, angiogenesis, metastasis, and bone degradation, all important events in the pathogenesis of cancer. Multiple myeloma is a B-cell cancer characterized by the proliferation of malignant plasma cells in the bone marrow, increased angiogenesis, and the development of osteolytic bone disease. The role of MMPs in the development of multiple myeloma is poorly understood. Using SC-964, a potent inhibitor of several MMPs (MMP-2, -3, -8, -9, and -13), we investigated the role of MMPs in the 5T2MM murine model. Reverse transcriptase-polymerase chain reaction demonstrated the presence of mRNA for MMP-2, -8, -9, and -13 in 5T2MM-diseased bone marrow. Mice bearing 5T2MM cells were given access to food containing SC-964. The concentration of SC-964 measured in the plasma of mice after 11 days of treatment was able to inhibit MMP-9 activity in gelatin zymography. Treatment of 5T2MM-bearing mice resulted in a significant reduction in tumor burden, a significant decrease in angiogenesis, and partially protective effect against the development of osteolytic bone disease. The direct role of MMPs in these different processes was confirmed by in vitro experiments. All these results support the multifunctional role of MMPs in the development of multiple myeloma. [less ▲]

Detailed reference viewed: 22 (1 ULg)